A Phase 1, Open-label Trial of AU-011 (Belzupacap Sarotalocan) in NMIBC
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The main objectives of this study are i) to evaluate the incidence of AU-011
treatment-related adverse events, serious adverse events (SAEs) and dose-limiting toxicities
(DLTs) and ii) to determine the feasibility of AU-011 treatment of non-muscle invasive
bladder cancer utilizing intramural with or without intratumoral injection.